ML 786 dihydrochloride

Discontinued Product

ML 786 dihydrochloride (Cat. No. 5036) has been withdrawn from sale for commercial reasons.
Cat.No. 5036 - ML 786 dihydrochloride | C29H29F3N4O3.2HCl | CAS No. 1237536-18-3
Description: Potent Raf kinase inhibitor; orally bioavailable
Alternative Names: BGB659
Chemical Name: 3-(1-Amino-1-methylethyl)-N-[(2R)-1,2,3,4-tetrahydro-7-oxo-1,8-naphthryridin-4-yl)oxy]-2-naphthalenyl]-5-benzamide dihydrochloride
Purity: ≥98% (HPLC)
Datasheet
Citations (1)
Reviews
Literature (3)

Biological Activity

Potent Raf kinase inhibitor (IC50 values are 2.1, 2.5 and 4.2 nM for B-RafV600E, C-Raf and wild-type B-Raf respectively). Also inhibits Abl-1, DDR2, EPHA2 and RET tyrosine kinase activity. Inhibits pERK formation and attenuates tumor growth in melanoma cell xenografts expressing the B-RafV600E mutation in vivo. Orally bioavailable.

Compound Libraries

ML 786 dihydrochloride is also offered as part of the Tocriscreen Plus. Find out more about compound libraries available from Tocris.

Technical Data

M. Wt 611.48
Formula C29H29F3N4O3.2HCl
Storage Store at +4°C
Purity ≥98% (HPLC)
CAS Number 1237536-18-3
PubChem ID 90488999
InChI Key DNMWHXHMDZCGEX-GHVWMZMZSA-N
Smiles O=C(N[C@@H]2CCC(C=CC(OC4=C(CC5)C(NC=C4)=NC5=O)=C3)=C3C2)C1=CC(C(F)(F)F)=CC(C(N)(C)C)=C1.Cl.Cl

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Tocris products are intended for laboratory research use only, unless stated otherwise.

References

References are publications that support the biological activity of the product.

Gould et al (2011) Design and optimization of potent and orally bioavailable tetrahydronaphthalene Raf inhibitors. J.Med.Chem. 54 1836 PMID: 21341678

Sase et al (2018) Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2-amplified gastric cancer. Mol.Cancer Ther. 17 2217 PMID: 30045926

View Related Products by Target

View Related Products by Product Action

View all Raf Kinase Inhibitors

Keywords: ML 786 dihydrochloride, ML 786 dihydrochloride supplier, ML786, dihydrochloride, potent, raf, kinase, inhibitors, inhibits, b-raf, c-raf, V600E, mutation, tyrosine, kinases, BGB659, Raf, Kinase, 5036, Tocris Bioscience

1 Citation for ML 786 dihydrochloride

Citations are publications that use Tocris products. Selected citations for ML 786 dihydrochloride include:

Sase et al (2018) Acquired JHDM1D-BRAF fusion confers resistance to FGFR inhibition in FGFR2- amplified gastric cancer. Mol.Cancer Ther. PMID: 30045926


Reviews for ML 786 dihydrochloride

There are currently no reviews for this product. Be the first to review ML 786 dihydrochloride and earn rewards!

Have you used ML 786 dihydrochloride?

Submit a review and receive an Amazon gift card.

$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image

$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image

$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image

Submit a Review

Literature in this Area

Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!

*Please note that Tocris will only send literature to established scientific business / institute addresses.


Cancer

Cancer Research Product Guide

A collection of over 750 products for cancer research, the guide includes research tools for the study of:

  • Cancer Metabolism
  • Epigenetics in Cancer
  • Receptor Signaling
  • Cell Cycle and DNA Damage Repair
  • Angiogenesis
  • Invasion and Metastasis
Immunology

Immunology Product Listing

A collection of over 190 products for immunology research, the guide includes research tools for the study of:

  • Chemokine and Cytokine Signaling
  • Chemotaxis
  • Complement System
  • Immune Cell Signaling
  • Inflammation
Kinases

Kinases Product Listing

A collection of over 400 products for kinase research, the listing includes inhibitors of:

  • Receptor Tyrosine Kinases
  • Protein Kinases A, C, D and G
  • PI-3 Kinase, Akt and mTOR
  • MAPK Signaling
  • Receptor Serine/Threonine Kinases